Skip to main content

Market Overview

Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma


Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation study STELLAR-001.

  • The study will add three new cohorts that will evaluate the safety and tolerability of Exelixis' XL092, in combination with Merck/Pfizer's Bavencio (avelumab), in patients with locally advanced or metastatic urothelial carcinoma (UC).
  • Exelixis is sponsoring the STELLAR-001 trial, and Merck KGaA and Pfizer will provide avelumab for use in the trial.
  • Additional expansion cohorts include maintenance therapy, patients who have progressed following treatment with an immune checkpoint inhibitor, and patients previously treated with platinum-containing chemotherapy.
  • XL092 is an investigational, next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in the growth and spread of cancer.
  • Price Action: EXEL shares are trading 0.86% higher at $23.35 in premarket trading on the last check Thursday.

Related Articles (MKGAF + MKKGY)

View Comments and Join the Discussion!

Posted-In: Urothelial CancerBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at